Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefathiamidine is a first-generation cephalosporin antibiotic. It is a beta-lactam antimicrobial agent that works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Cefathiamidine is primarily used in China and some other countries for the treatment of infections caused by susceptible Gram-positive and some Gram-negative bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and sepsis. Its mechanism of action involves binding to penicillin-binding proteins (PBPs), thereby blocking the transpeptidation step in peptidoglycan synthesis essential for bacterial cell wall integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefathiamidine.